Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIEL F SOTERES

Allopathic & Osteopathic Physicians Allergy & Immunology Allergy

NPI
1679573588
CMS profile
212108
Location
COLORADO SPRINGS, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$67,012.04

197 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIEL F SOTERES

NPI 1679573588 · CMS profile ID 212108

Allopathic & Osteopathic Physicians / Allergy & Immunology / Allergy

COLORADO SPRINGS, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679573588?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIEL F SOTERES, NPI 1679573588, CMS profile ID 212108. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679573588?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). DANIEL F SOTERES, NPI 1679573588, CMS profile ID 212108. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679573588?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
DANIEL F SOTERES, NPI 1679573588, CMS profile ID 212108, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 197 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1679573588?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

197 matching records · $67,012.04 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 197 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 197.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $16.2910/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927419527 CMS
GlaxoSmithKline, LLC. $21.2810/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944469263 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1.4410/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955835681 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2.0210/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955835685 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3.4210/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955835689 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.9710/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955835693 CMS
Takeda Pharmaceuticals U.S.A., Inc. $465.0009/30/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955835677 CMS
AstraZeneca Pharmaceuticals LP $3.1109/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914781005 CMS
AstraZeneca Pharmaceuticals LP $16.2709/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915061887 CMS
Regeneron Healthcare Solutions, Inc. $12.6509/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927419519 CMS
Amgen Inc. $17.5009/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939197701 CMS
GENZYME CORPORATION $10.1109/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938881027 CMS
AstraZeneca Pharmaceuticals LP $16.3209/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915062432 CMS
kaleo, Inc. $15.8509/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941013193 CMS
Takeda Pharmaceuticals U.S.A., Inc. $749.2009/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955835673 CMS
CSL Behring $29.4709/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940843531 CMS
Takeda Pharmaceuticals U.S.A., Inc. $7.9409/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955835669 CMS
Regeneron Healthcare Solutions, Inc. $7.7809/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927419511 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.2009/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955835666 CMS
GlaxoSmithKline, LLC. $6.4909/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944469209 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.5708/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887762901 CMS
CSL Behring $1,000.0008/31/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940843571 CMS
GENZYME CORPORATION $18.9708/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938881015 CMS
OptiNose US, Inc. $24.8308/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928083687 CMS
Takeda Pharmaceuticals U.S.A., Inc. $61.8808/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955835657 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.1208/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955835663 CMS
Pharming Healthcare, Inc. $1,800.0008/19/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 907881093 CMS
GlaxoSmithKline, LLC. $4.6708/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944469247 CMS
Takeda Pharmaceuticals U.S.A., Inc. $8.6008/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955835653 CMS
Regeneron Healthcare Solutions, Inc. $5.8008/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927419501 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,441.2508/11/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955835641 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.3608/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955835645 CMS
Takeda Pharmaceuticals U.S.A., Inc. $7.8008/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955835649 CMS
Amgen Inc. $12.4708/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939197699 CMS
Takeda Pharmaceuticals U.S.A., Inc. $26.3308/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955835634 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2.6408/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955835637 CMS
AstraZeneca Pharmaceuticals LP $76.7907/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915258131 CMS
Takeda Pharmaceuticals U.S.A., Inc. $54.6707/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955835631 CMS
BioCryst US Sales Co., LLC $42.6807/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946866651 CMS
OptiNose US, Inc. $119.4607/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928083831 CMS
Amgen Inc. $18.0307/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939197697 CMS
GlaxoSmithKline, LLC. $7.8707/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944469231 CMS
GlaxoSmithKline, LLC. $12.0407/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944469267 CMS
BioCryst US Sales Co., LLC $17.0107/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946866655 CMS
GENZYME CORPORATION $19.5007/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938880999 CMS
Regeneron Healthcare Solutions, Inc. $4.8107/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927419493 CMS
CSL Behring $41.8207/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940843503 CMS
BioCryst US Sales Co., LLC $275.0007/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946866595 CMS
Takeda Pharmaceuticals U.S.A., Inc. $28.9907/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955835621 CMS
Takeda Pharmaceuticals U.S.A., Inc. $5.5707/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955835625 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $100,898.67 176
PY2020 $41,299.14 124
PY2021 $72,085.49 195
PY2022 $67,012.04 197
PY2023 $130,153.08 281
PY2024 $122,810.91 242
PY2025 $115,773.97 260

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $693,814.55 70
PY2024 Principal investigator $899,112.72 58
PY2023 Principal investigator $685,808.60 98
PY2022 Principal investigator $515,302.70 98
PY2021 Recipient $29.95 1
PY2021 Principal investigator $739,491.48 163
PY2020 Principal investigator $358,959.54 108
PY2019 Principal investigator $478,254.04 76

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

70 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $25,750.00 12/17/2025 Non-covered Recipient Entity
ASTHMA AND ALLERGY ASSOCIATES, PC
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190309254
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,526.55 11/25/2025 Non-covered Recipient Entity
ASTHMA AND ALLERGY ASSOCIATES, PC
a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma No dispute reported 06/30/2026 1185541116
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,260.00 11/19/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223288447
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $707.00 11/19/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223288449
Principal investigator 1 Novartis Pharmaceuticals Corporation $135.48 11/15/2025 Non-covered Recipient Entity
ASTHMA AND ALLERGY ASSOCIATES, PC
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi No dispute reported 06/30/2026 1190306075
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,212.17 11/10/2025 Non-covered Recipient Entity
ASTHMA AND ALLERGY ASSOCIATES, PC
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190306077
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,044.00 10/15/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286779
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,044.00 10/15/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286781
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $536.00 10/15/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286783
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $707.00 10/15/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286785
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $536.00 10/15/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286787
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,015.00 10/15/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223286789
Principal investigator 1 Novartis Pharmaceuticals Corporation $23,855.00 09/23/2025 Non-covered Recipient Entity
ASTHMA ALLERGY ASSOCIATES PC
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190307145
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,260.00 09/17/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223285466
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $707.00 09/17/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223285468
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,260.00 09/17/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223285470
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,015.00 09/17/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223285472
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,015.00 08/11/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284095
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,015.00 08/11/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223284097
Principal investigator 1 AstraZeneca Pharmaceuticals LP $36,931.96 07/31/2025 Non-covered Recipient Entity
ASTHMA AND ALLERGY ASSOCIATES, PC
ALTA - Albuterol budesonide Treatment in Acute airway obstruction his is a multi-center randomized double-blind 2-period cross-over study evaluating efficacy and safety of repeated doses of PT027 albuterol budesonide pressurized metered dose inhaler pMDI compared to PT007 albuterol pMDI in participants with asthma and acute airway obstruction induced by 2 mannitol challenges 7 hours apart No dispute reported 06/30/2026 1185541112
Principal investigator 1 Novartis Pharmaceuticals Corporation $910.28 07/21/2025 Non-covered Recipient Entity
ASTHMA AND ALLERGY ASSOCIATES, PC
A 52-week multicenter, randomized, double-blind, placebo-controlled study to assess efficacy and safety of remibrutinib (LOU064) in adult and adolescent participants with IgE-mediated food allergy. No dispute reported 06/30/2026 1190308344
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,015.00 07/16/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282624
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,265.50 07/02/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282078
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,015.00 06/18/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281462
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,015.00 06/18/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281464
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,174.00 06/18/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281466
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,083.00 06/18/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281468
Principal investigator 1 Novartis Pharmaceuticals Corporation $95,887.93 06/15/2025 Non-covered Recipient Entity
ASTHMA AND ALLERGY ASSOCIATES, PC
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190308340
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,439.00 05/14/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279410
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $934.00 05/14/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279412
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,015.00 05/14/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279448
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $497.00 05/14/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279450
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,015.00 05/14/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279452
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,424.00 05/14/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279454
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $497.00 05/14/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279456
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $497.00 05/14/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223279458
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,174.00 04/18/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278330
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,083.00 04/18/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278332
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,260.00 04/18/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278334
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,174.00 04/18/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278336
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,083.00 04/18/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278338
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,525.00 04/16/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278086
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,652.00 04/16/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278088
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $574.00 04/16/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278090
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,120.00 04/16/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278092
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 04/16/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223278094
Principal investigator 1 Eli Lilly and Company $13,365.00 04/10/2025 Non-covered Recipient Entity
ASTHMA AND ALLERGY ASSOCIATES, PC
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187877115
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,439.00 03/14/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276369
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,439.00 03/14/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276371
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $934.00 03/14/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276373
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,439.00 03/14/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276375
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $934.00 03/14/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276377
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,439.00 03/14/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276407
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $934.00 03/14/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276409
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,424.00 03/14/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276411
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $497.00 03/14/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276413
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,260.00 03/14/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276425
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $497.00 03/14/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276427
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,424.00 03/14/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276429
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $497.00 03/14/2025 Non-covered Recipient Entity
ASTHMA & ALLERGY ASSOCIATES PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223276431
Principal investigator 1 Novartis Pharmaceuticals Corporation $33,847.94 02/27/2025 Non-covered Recipient Entity
ASTHMA ALLERGY ASSOCIATES PC
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190307143
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,970.00 02/26/2025 Non-covered Recipient Entity
ASTHMA AND ALLERGY ASSOCIATES, PC
ALTA - Albuterol budesonide Treatment in Acute airway obstruction his is a multi-center randomized double-blind 2-period cross-over study evaluating efficacy and safety of repeated doses of PT027 albuterol budesonide pressurized metered dose inhaler pMDI compared to PT007 albuterol pMDI in participants with asthma and acute airway obstruction induced by 2 mannitol challenges 7 hours apart No dispute reported 06/30/2026 1185541118
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,874.53 02/24/2025 Non-covered Recipient Entity
ASTHMA AND ALLERGY ASSOCIATES, PC
A Multicenter,Single arm,Open label,Post Authorization,Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under Studied Populations in the United States No dispute reported 06/30/2026 1185541114
Principal investigator 1 AstraZeneca Pharmaceuticals LP $45,083.66 02/20/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
ALTA - Albuterol budesonide Treatment in Acute airway obstruction his is a multi-center randomized double-blind 2-period cross-over study evaluating efficacy and safety of repeated doses of PT027 albuterol budesonide pressurized metered dose inhaler pMDI compared to PT007 albuterol pMDI in participants with asthma and acute airway obstruction induced by 2 mannitol challenges 7 hours apart No dispute reported 06/30/2026 1185541120
Principal investigator 1 Novartis Pharmaceuticals Corporation $193,757.92 01/30/2025 Non-covered Recipient Entity
ASTHMA ALLERGY ASSOCIATES PC
A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy No dispute reported 06/30/2026 1190306285
Principal investigator 1 Novartis Pharmaceuticals Corporation $48,958.00 01/30/2025 Non-covered Recipient Entity
ASTHMA ALLERGY ASSOCIATES PC
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co No dispute reported 06/30/2026 1190306287
Principal investigator 1 Novartis Pharmaceuticals Corporation $24,648.00 01/28/2025 Non-covered Recipient Entity
ASTHMA ALLERGY ASSOCIATES PC
A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy No dispute reported 06/30/2026 1190306289
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,479.52 01/01/2025 Non-covered Recipient Entity
ASTHMA AND ALLERGY ASSOCIATES, PC
A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy No dispute reported 06/30/2026 1190308342
Principal investigator 1 Novartis Pharmaceuticals Corporation $21,479.20 01/01/2025 Non-covered Recipient Entity
ASTHMA AND ALLERGY ASSOCIATES, PC
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co No dispute reported 06/30/2026 1190308346
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,832.91 01/01/2025 Non-covered Recipient Entity
ASTHMA AND ALLERGY ASSOCIATES, PC
A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy No dispute reported 06/30/2026 1190308348